PMID: 7518661Jun 1, 1994Paper

Treatment strategy to obtain cure for recurrent advanced breast cancer

Gan to kagaku ryoho. Cancer & chemotherapy
M Ogawa, T Mukaiyama

Abstract

The three-year survival rate of a total of 186 patients with recurrent advanced breast cancer was 86% for complete responders, 27% for partial responders, and 29% for patients remaining in stable diseases, respectively, at our two institutions. Thus, the results indicated that a complete response is the first step for long-term survival. High-dose chemotherapy with autologous stem cell support was administered after 4 cycles of induction chemotherapy. The results showed 12 complete response (60%) out of 20 patients, and 5 cases survived with no evidences of disease for 5-31 months. Both taxol and taxotere achieved response rates exceeding 50% in phase II trials on advanced breast cancer and therefore were expected to have a role in combination regimens with other drugs.

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.